Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

NCT03831438
completedphase_1

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

NCT03834662
completedphase_1

MPN-RC 118 AVID200 in Myelofibrosis

NCT03895112

Clinical Trials (3)

Showing 3 of 3 trials
NCT03831438Phase 1

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

Completed
NCT03834662Phase 1

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Completed
NCT03895112Phase 1

MPN-RC 118 AVID200 in Myelofibrosis

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3